5 Best Peptides for Bell's Palsy

What to Know Before Choosing a Peptide for Bell's Palsy

Bell's Palsy sits at a crossroads that makes peptide research genuinely interesting and genuinely difficult at the same time. It is a condition with a well-established standard treatment: corticosteroids started within 72 hours give most people a strong chance of full recovery. But a meaningful subset of people, those recovering more slowly, those past the acute window, or those simply wanting to support the regeneration process from every angle, look beyond standard care toward compounds that might nudge nerve repair along.

No peptide has been tested in a completed randomized controlled trial specifically for Bell's Palsy as of 2026. That is the honest field-wide reality, stated once here rather than repeated in every entry. What exists is a small set of compounds that people use or are actively discussing for this goal: some with clinical testing in adjacent nerve conditions, some with animal-model data pointing toward facial nerve regeneration, and some whose use is primarily community-reported. Every compound in this guide earned its slot because people use it or are discussing it for Bell's Palsy recovery, not because it cleared an FDA approval bar. FDA-approved, telemedicine-prescribed, and research-only compounds are all represented, and the evidence behind each is described honestly inside its entry.

The entries are numbered by how prominently each compound appears in research and documented real-world use, not as a verdict on which one is better than another for any individual. Number one is not a recommendation. The right compound for a given person depends on recovery stage, individual circumstances, and what they build with a knowledgeable provider. Think of the numbering as a map from most-discussed to least-discussed, nothing more.

One point worth holding before entry one: none of these compounds replaces the standard corticosteroid protocol. They are used as adjuncts to medical care, and anyone considering them should do so in consultation with a physician, particularly given the regulatory complexity covered in each entry.

1. Cerebrolysin: The Most Clinically Tested Option for Nerve Recovery

Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides and free amino acids derived from purified pig brain proteins. That description sounds unusual, but the clinical track record it has built across neurological conditions makes it the most evidence-supported peptide in the Bell's Palsy conversation. In countries across Europe and Asia, Cerebrolysin is an approved therapy used in hospital settings for stroke, traumatic brain injury, and dementia. Within Bell's Palsy discussions, it is recognized as the one peptide with clinical testing specifically noted as an adjunct for facial nerve recovery.

The mechanism makes intuitive sense for this condition. Cerebrolysin contains peptide fragments that appear to mimic the action of endogenous neurotrophic factors, the naturally produced proteins the nervous system uses to keep neurons alive, promote axon growth, and drive the kind of plasticity underlying genuine nerve repair. The most relevant of these are BDNF, NGF, and GDNF, abbreviated names for proteins that act as growth and survival signals for nerve tissue. When the facial nerve has been compressed, inflamed, and partially demyelinated, as happens in Bell's Palsy, having more of that neurotrophic signaling around the recovering nerve is the theoretical goal. Cerebrolysin's peptide content appears to provide it.

Within Bell's Palsy discussions, Cerebrolysin is described as the only peptide with clinically tested adjunct status for speeding recovery. Specific trial names and outcome numbers were not detailed in the Bell's Palsy-specific literature reviewed for this guide, so the honest characterization is this: its clinical evidence profile is stronger than every other option on this list, but the published trial data specific to Bell's Palsy is less thoroughly available than its neurological stroke and dementia literature. In the United States, Cerebrolysin is not FDA-approved for any indication and is obtained through research suppliers or integrative clinics. Where it is clinically approved, it is administered by intramuscular or intravenous injection under medical supervision. Anyone pursuing it in the US should understand they are operating in a research-use context, not a standard-of-care one.

2. BPC-157: The Most Discussed for General Nerve and Tissue Repair

BPC-157, which stands for Body Protection Compound 157, is a synthetic 15-amino-acid peptide originally derived from a protein found in gastric juice. It is one of the most widely discussed peptides in recovery and biohacking communities, and that broad reputation for tissue repair and anti-inflammatory effects is exactly how it enters the Bell's Palsy conversation.

The proposed mechanism for this goal centers on three overlapping properties: anti-inflammatory effects that could reduce the swelling compressing the facial nerve, promotion of angiogenesis (the growth of new blood vessels) to improve blood supply to recovering nerve tissue, and general soft tissue and nerve repair activity observed in animal research. BPC-157 has a genuine preclinical literature in rodent models across a range of tissue types, and some of that data touches on nervous system injury. The translation to facial nerve repair specifically has not been established in published human research.

No human clinical trials have been published for BPC-157 in Bell's Palsy as of 2026. The use case here is anecdotal, drawn from functional medicine practitioners who mention it for nerve and immune neuropathy contexts and from peptide community discussions where it is frequently named. Some community members note that BPC-157 may not significantly address direct nerve damage the way a neurotrophic-specific compound like Cerebrolysin might, which is a reasonable read of the mechanistic picture. It is used for the general repair and anti-inflammatory support it is known for in other contexts, extrapolated to the facial nerve situation.

On the regulatory side, the FDA has explicitly flagged BPC-157 as not approved for human use and has raised concerns about immunogenicity and manufacturing impurities from research-grade sources. It is not legally prescribed under standard medical practice in the United States, though some compounding pharmacies and integrative clinics operate in a gray area under physician oversight. Anyone considering it should weigh that regulatory reality carefully.

3. ARA-290: For the Neuroinflammation and Nerve Pain Component

ARA-290 is a synthetic peptide derived from erythropoietin, the hormone that regulates red blood cell production. What makes it relevant to Bell's Palsy is not the erythropoietin connection but where its research has focused: neuroinflammation, neuropathic pain, and the protection of small nerve fibers. ARA-290 works by targeting innate repair receptors on nerve tissue, a class of receptors that, when activated, appear to dampen neuroinflammatory signaling and support nerve fiber survival without the immunosuppressive side effects that accompany steroids.

For Bell's Palsy, the reasoning is mechanistic extrapolation rather than direct study. The condition involves inflammation of the facial nerve as a central feature, and the residual nerve pain and sensory disturbance some people experience during and after recovery represent exactly the kind of neuropathic pain state where ARA-290's studied mechanisms would theoretically apply. It has been investigated in small fiber neuropathy research and in neuropathic pain contexts in both human and animal settings, though none of that research was conducted in Bell's Palsy populations specifically.

No clinical trial data exists for ARA-290 in this specific context as of 2026. It appears in Bell's Palsy community discussions as an option for people whose primary struggle is the pain and inflammation component rather than motor recovery. Regulatory status mirrors the others on this list: it is not FDA-approved for any Bell's Palsy-related indication and is used as a research compound.

4. IGF-1: For Early Axon Regeneration Support

Insulin-like growth factor 1, commonly abbreviated as IGF-1, is an endogenous peptide hormone with a significant role in growth and cellular repair throughout the body. Its relevance to Bell's Palsy comes from a more specific function: supporting neuronal survival and axon regeneration after nerve injury.

IGF-1 promotes the survival of neurons under stress, stimulates axon sprouting and growth, and supports Schwann cells, the specialized cells that wrap peripheral nerve fibers in myelin and are essential to re-establishing the insulating sheath a demyelinated nerve needs to function properly again. In animal models of peripheral nerve injury, IGF-1 has produced measurable improvements in nerve fiber regeneration. One published study examined topical delivery of IGF-1 via a hydrogel vehicle in a peripheral facial nerve palsy model and reported a beneficial effect, which is the most Bell's Palsy-adjacent published finding available for this compound.

That study represents the current ceiling of published evidence for IGF-1 in this context. No completed human randomized controlled trials exist for Bell's Palsy specifically, and the topical hydrogel delivery method studied differs considerably from the injectable or systemic forms of IGF-1 that appear in research compound discussions. Facial Palsy UK has mentioned growth factors including IGF-1 as a direction for potential future research, which signals scientific interest rather than established use. In the United States, IGF-1 as a medication carries FDA approval only for the narrow indication of severe IGF-1 deficiency in children, not for nerve repair or Bell's Palsy. Its presence in peptide conversations for this goal rests on the nerve-regeneration rationale rather than a Bell's Palsy-specific protocol.

5. PACAP: A Neuropeptide the Body Already Uses for Facial Nerve Repair

PACAP, which stands for Pituitary Adenylyl Cyclase-Activating Polypeptide, occupies a different category from the compounds above. It is not an externally administered research compound someone found a nerve-repair rationale for. It is one of the endogenous neuropeptides the human body produces naturally as part of the facial nerve regeneration process itself.

Animal research on facial nerve injury has found that PACAP increases in injured nerve tissue, provides neurotrophic factors to support axon regrowth, promotes remyelination, and improves neuromuscular recovery in those models. It appears to act as a regulatory signal that coordinates the cellular environment around a damaged nerve, marshaling the resources needed for repair. Some researchers consider PACAP expression a marker of active facial nerve regeneration in animal models, because its presence reflects ongoing repair activity rather than a static state.

The distinction between being an endogenous repair molecule and being an available therapeutic compound matters here. Animal studies of facial nerve injury have shown that administering exogenous PACAP can accelerate recovery beyond what happens spontaneously. But there are no human clinical trials for PACAP in Bell's Palsy as of 2026, and PACAP is not currently available as a standard research compound through the channels that supply the other peptides on this list. Its place in this guide is as a scientifically grounded entry: the body itself recruits PACAP for facial nerve repair, and that biological fact is part of why neuropeptide-based approaches to this condition continue to attract research interest. For people tracking the direction of Bell's Palsy science, PACAP represents a mechanistically sound target. For people looking for something available to use now, the compounds earlier in this guide are more practically relevant.

How These Peptides Compare

Frequently Asked Questions

Is any peptide FDA-approved specifically for Bell's Palsy?

No peptide is currently FDA-approved for Bell's Palsy. The only treatments with strong human trial evidence for this condition are corticosteroids, specifically prednisolone, started within 72 hours of symptom onset. The peptides discussed in this guide are used as adjuncts by people interested in supporting the nerve regeneration process, and all of them operate in a research or off-label context in the United States.

Can peptides replace the standard corticosteroid treatment for Bell's Palsy?

No, and this distinction matters for outcomes. Corticosteroids address the acute inflammation compressing the facial nerve and have the strongest evidence for early recovery. The peptides discussed here are used as adjuncts alongside standard medical treatment, not instead of it. Anyone pursuing peptide support for Bell's Palsy should do so in consultation with their treating physician, particularly given the regulatory status of the compounds involved.

How long does Bell's Palsy recovery typically take, and does that affect which peptide approach makes sense?

Most people with Bell's Palsy see significant improvement within three to six months, and roughly 70 to 80 percent recover fully without any intervention beyond standard care. Recovery stage does affect the theoretical rationale for different compounds: neurotrophic support like Cerebrolysin is aimed at the regeneration phase following the acute inflammatory period, while ARA-290 targets the ongoing neuroinflammation and nerve pain that can persist into recovery. The research is not yet specific enough to assign any peptide to a particular recovery window with clinical confidence.

Where do people obtain peptides for Bell's Palsy?

Access varies significantly by compound and country. Cerebrolysin is clinically approved and prescribed in parts of Europe and Asia. In the United States, the compounds discussed here are obtained through integrative medicine clinics, compounding pharmacies operating under physician oversight, or research supplier channels, none of which represent FDA-approved use for this condition. Anyone exploring these options should understand the regulatory landscape and work with a healthcare provider familiar with it.

Are there safety concerns specific to using peptides for Bell's Palsy?

No verified safety data exists for any of these compounds used specifically in Bell's Palsy as of 2026. The FDA has flagged BPC-157 in particular for concerns including immunogenicity and impurities from research-grade manufacturing. Cerebrolysin has an acceptable tolerability profile in the neurological indications where it is clinically approved, but Bell's Palsy-specific safety data has not been published. Anyone considering these compounds should treat them as experimental in this context and seek medical guidance rather than self-directing their use.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for Bell's Palsy in one place.